alpha-linolenic acid
metaboliteAlpha-linolenic acid dysregulation in young adults with acute myocardial infarction reflects disrupted lipid metabolism and oxidative stress.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationalePolyunsaturated fatty acid; lipid metabolism dysregulation in AMI.
Also acts inLipid entry/oxidation
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I56
C — non-Type-I58
A — assay feasibility42
E — evidence strength25
T1DI (composite)5
Specificity differential (R−C)-2.1
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Targeted metabolomic analysis of plasma fatty acids in acute myocardial infarction in young adults.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2021 · PMID 34625358 · doi
Clinical trials(1)
- Inflammatory Indicators and Arterial Stiffness in Patients With Severe Obesity. Response to Supplementation of Alpha Linolenic AcidNCT00502021 · PHASE2 · UNKNOWN · Placebo, Alpha-linolenic acid/ALA, Alpha linolenic acid/ALA, Placebo